MetaCap

Seres Therapeutics (MCRB) vs Tvardi Therapeutics (TVRD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tvardi Therapeutics is the larger company by market cap ($13.2 million vs $12.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MCRB-54.41%TVRD-10.06%
+32%-13%-59%
Oct 7, 20261 yearNov 20, 2026
MCRB-54.24%TVRD-3.95%
+18%-20%-58%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MCRB versus TVRD key metrics
MetricMCRBTVRD
Share price$1.24$0.9893
Market cap$12.64M$13.22M
1-day change-6.77%+4.57%
YTD return—-76.99%
1-year return—-74.76%
5-year return—-99.79%
EPS (TTM)$-5.01$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$789.00K—
Net income (latest FY)$5.70M$-18.21M
Operating margin-11910.14%—
Net margin721.93%—
52-week high$18.86$5.69
52-week low$1.20$0.773
Distance from 52-week high-93.43%-82.61%
Analyst consensusnonebuy
Avg. price target upside+1270.97%+835.00%
Average volume74.83K235.95K
Shares outstanding10.20M13.36M
Employees6612
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Seres Therapeutics

MCRB stock →

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

About Tvardi Therapeutics

TVRD stock →

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

MCRB vs TVRD FAQ

Which is bigger, Seres Therapeutics or Tvardi Therapeutics?

Tvardi Therapeutics (TVRD) is larger, with a market capitalization of $13.22M compared with $12.64M for Seres Therapeutics (MCRB).

Are Seres Therapeutics and Tvardi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons